MedPage Today) -- A pembrolizumab (Keytruda) combination led to an overall survival (OS) boost in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer, according to results from the KEYNOTE-A18 trial...
TheFeel, námestí Smirických, Kostelec n. C. Lesy 28163, Czechia
+31613054419
info@thefeel.org
Copyright © 2023 news.thefeel.org. All Rights Reserved
